share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  05/03 06:06
Moomoo AI 已提取核心信息
Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of May 2, 2024. The company's filing, identified by accession number 0001493152-24-017464 and submission type POS AM, has been acknowledged by the SEC, marking a pivotal step in Conduit Pharmaceuticals' regulatory journey. The effectiveness of this submission is a key development for the company, which is listed under the CIK number 0001896212 and file number 333-275056.
Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of May 2, 2024. The company's filing, identified by accession number 0001493152-24-017464 and submission type POS AM, has been acknowledged by the SEC, marking a pivotal step in Conduit Pharmaceuticals' regulatory journey. The effectiveness of this submission is a key development for the company, which is listed under the CIK number 0001896212 and file number 333-275056.
Conduit Pharmicals Inc.取得了重要的里程碑,美国证券交易委员会(SEC)宣布其提交的文件自2024年5月2日起生效。该公司的申请以注册号0001493152-24-017464确定,提交类型为POS AM,已得到美国证券交易委员会的认可,这标志着Conduit Pharmaceuticals监管之旅迈出了关键的一步。本次提交的有效性是该公司的一项关键进展,该公司在CIK上市,编号为0001896212,文件编号为333-275056。
Conduit Pharmicals Inc.取得了重要的里程碑,美国证券交易委员会(SEC)宣布其提交的文件自2024年5月2日起生效。该公司的申请以注册号0001493152-24-017464确定,提交类型为POS AM,已得到美国证券交易委员会的认可,这标志着Conduit Pharmaceuticals监管之旅迈出了关键的一步。本次提交的有效性是该公司的一项关键进展,该公司在CIK上市,编号为0001896212,文件编号为333-275056。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息